Alzamend Neuro Inc (9ZT0.MU)
Chart Events
Performance Outlook
| Previous Close | 0.2000 |
| Open | 0.1960 |
| Bid | 0.1900 x N/A |
| Ask | 0.2160 x N/A |
| Day's Range | 0.1960 - 0.1960 |
| 52 Week Range | 0.1900 - 1.4788 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for 9ZT0.MU
Related Research
Business WireAlzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement
ATLANTA, September 22, 2023--Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement
BenzingaEXCLUSIVE: Alzamend Seeks FDA Approval For Study For Upgraded Version Of Most Commonly Used Treatment For Bipolar Disorder
Alzamend Neuro Inc (NASDAQ: ALZN) has submitted an investigational new drug (IND) application to the FDA to initiate AL001-BD01, a Phase 2A study of AL001 for bipolar disorder. Lithium is a commonly prescribed drug for manic episodes in bipolar disorder type 1 and maintenance therapy for bipolar disorder in patients with a history of manic episodes. AL001 is a novel lithium-delivery system that can potentially deliver the benefits of marketed lithium salts while mitigating or avoiding currently
Business WireAlzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients
ATLANTA, August 30, 2023--Alzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug, in Bipolar Disorder Patients
